Er is geen medische onderzoek beschikbaar over de werking van Methoxetamine in het menselijk lichaam. Dit heeft in grote maten te maken met de ontwikkeling van Methoxetamine als research chemical. Er is er naar mijn mening te weinig informatie beschikbaar om echt te kunnen speculeren over het contrast tussen de schade veroorzaakt door MXE en Ketamine.
Pharmacology:
The mechanism of action is reported to involve NMDA receptor blockade and
dopamine reuptake inhibition, although formal pharmacology has not been
determined (Ward, 2011).
Health risks
Toxicity and adverse effects:
Wood et al (2011) (United Kingdom) report a case series of three individuals with
acute toxicity related to the analytically confirmed use of methoxetamine. The paper
reports clinical features suggestive of a “dissociative/catatonic” state similar to that seen with ketamine and clinical features of acute sympathomimetic toxicity with
significant tachycardia and hypertension.
Hofer et al (2011) (Switzerland, Austria) report an analytically confirmed case of
intravenous methoxetamine use. The observed symptoms were tachycardia,
hypertension, confusion, agitation, stupor, ataxia, mydriasis, and nystagmus. The
paper also suggests that the effects were consistent with ketamine-induced adverse
effects and resolved with symptomatic treatment.
Intoxication and treatment:
Side effects include anxiety, blurred vision, impaired concentration, sympathomimetic
effects (tachycardia), nausea, possibly panic attacks, insomnia. Loss of consciousness
appears at very high dosages.
Intoxication can lead to neurological impairment and reversible cerebellar toxicity,
which in most cases resolves spontaneously after 24 hours, but in some cases can last
for several days. Treatment of overdosage is mainly supportive and symptomatic, no
specific antidote is available.
It is unclear whether methoxetamine demonstrates the same blatter toxicity that has
been reported after extensive use of ketamine.
Drugslijn.be - FACT SHEET - Methoxetamine - October 2013Recent is er een rapport uitgekomen waarin overzichten staan van recente bevindingen binnen Europa:
European Monitoring Centre for Drugs and Drug Addiction–Europol Joint Report
on a new psychoactive substance: methoxetamine (2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone)Op pagina 13 staan een aantal stukken over gezondheidsrisico assessment:
A first indication of the risks associated with the new psychoactive substance, including the health and social risks, and of the characteristics of users — Article 5.2(d) of the DecisionWat betreft de veiligheid van Ketamine staan er in dit topic enkele stukken uit recent onderzoek:
Brain damages in ketamine addicts as revealed by MRI (2013)
Geplaatst: di feb 18, 2014 7:29 pm
